What do systematic reviews say?

Intervention not reported

• Non‐invasive diagnostic tests for Helicobacter pylori infection 2018 · Cochrane Headline outcomes only
  no estimate extracted
  21 studies · 1810 participants
  GRADE not reported

Intervention not reported

• Non‐invasive diagnostic tests for Helicobacter pylori infection 2018 · Cochrane Headline outcomes only
  no estimate extracted
  34 studies · 4242 participants
  GRADE not reported

Intervention not reported

• Non‐invasive diagnostic tests for Helicobacter pylori infection 2018 · Cochrane Headline outcomes only
  no estimate extracted
  29 studies · 2988 participants
  GRADE not reported

Duodenal stenting vs surgical palliation

Duodenal stenting showed no clear difference in re‐establishment of oral intake (technical success of the… compared with surgical palliation (low certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  RR 0.98 [0.88, 1.09]
  3 studies · 82 participants
  Low

Duodenal stenting vs surgical palliation

Duodenal stenting showed no clear difference in time to re‐establishment of oral intake compared with surgical palliation (low certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 57 participants
  Low

Duodenal stenting vs surgical palliation

It is very uncertain whether duodenal stenting changes all‐cause mortality compared with surgical palliation (very low certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  RR 0.72 [0.14, 3.64]
  1 study · 27 participants
  Very low

Duodenal stenting vs surgical palliation

It is very uncertain whether duodenal stenting changes median survival postintervention compared with surgical palliation (very low certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 39 participants
  Very low

Duodenal stenting vs surgical palliation

Duodenal stenting showed no clear difference in time to recurrence of obstructive symptoms compared with surgical palliation (moderate certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  RR 5.08 [0.96, 26.74]
  2 studies · 57 participants
  Moderate

Duodenal stenting vs surgical palliation

It is very uncertain whether duodenal stenting changes adverse events compared with surgical palliation (very low certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  RR 1.15 [0.33, 3.98]
  3 studies · 84 participants
  Very low

Duodenal stenting vs surgical palliation

Duodenal stenting showed no clear difference in length of hospital stay compared with surgical palliation (moderate certainty).

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 84 participants
  Moderate

Duodenal stenting vs surgical palliation

The review found no eligible studies for this question.

• Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Usual care vs immunosuppressive withdrawal after monotherapy

Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 0.42 [0.24, 0.72]
  4 studies · 215 participants
  Low

Usual care vs immunosuppressive withdrawal after monotherapy

It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 0.34 [0.06, 2.08]
  2 studies · 135 participants
  Very low

Usual care vs immunosuppressive withdrawal after monotherapy

Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 0.88 [0.67, 1.17]
  3 studies · 186 participants
  Low

Usual care vs immunosuppressive withdrawal after monotherapy

It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 3.29 [0.35, 30.8]
  2 studies · 134 participants
  Very low

Usual care vs immunosuppressive withdrawal after monotherapy

It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 2.59 [0.35, 19.04]
  2 studies · 135 participants
  Very low

Usual care vs immunosuppressive withdrawal after combination therapy

Usual care showed no clear difference in relapse at 12 or 24 months compared with immunosuppressive withdrawal after combination therapy (low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 1.02 [0.68, 1.52]
  2 studies · 111 participants
  Low

Usual care vs immunosuppressive withdrawal after combination therapy

Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 1.11 [0.44, 2.81]
  2 studies · 111 participants
  Low

Usual care vs immunosuppressive withdrawal after combination therapy

It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).

• Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 1 [0.21, 4.66]
  1 study · 80 participants
  Very low

Cannabis cigarettes (115 mg THC) vs placebo cigarettes

It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).

• Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
  RR 4.55 [0.63, 32.56]
  1 study · 21 participants
  Very low